Use of Antipsychotics: A Study from the French National Insurance Healthcare System Database

Abstract

A marked increase in antipsychotic prescriptions has been observed in most countries since the introduction of second-generation antipsychotics. Misuse could partly explain this rise. We described the use of antipsychotic medication in France. This retrospective analysis was conducted on the sample “Echantillon généraliste de beneficiaries” from the French National Insurance Healthcare System. All reimbursements for antipsychotic medications in 2010 were identified. Antipsychotics use was described in terms of patient’s profiles and condition of use. In 2010, we identified 11,729 single patients with at least one reimbursement for antipsychotic medication (2.23% of French health insurance beneficiaries). The mean age in the population was 54 (sd 20) years. Forty-one percent had declared psychiatric disorder and 15% had a psychiatric follow-up for unknown diseases. Schizophrenia, others psychosis and personality disorders were the three main diagnoses of psychiatric disease. Patients without declared psychiatric disorders and without psychiatric follow-up accounted for 23% (aged between 15 and 65) and 20% (aged 65 years and over) of the population using antipsychotics. Forty-five percent of patients aged between 15 and 65 had more than 3 months of treatment refunded. Patients aged 65 years and over were 69% without dementia and 47% had more than three months of treatment of antipsychotics refunded during the year. These results suggested that antipsychotic treatments were used in France at long term in particular for patients without declared psychiatric disorder or psychiatric follow-up.

Share and Cite:

Désaméricq, G. , Schürhoff, F. , Macquin-Mavier, I. , Bachoud-Lévi, A. and Maison, P. (2015) Use of Antipsychotics: A Study from the French National Insurance Healthcare System Database. Pharmacology & Pharmacy, 6, 411-419. doi: 10.4236/pp.2015.68042.

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1] Haute Autorité de Santé (2012) Recommandation de Bonne Pratique—Maladie d’Alzheimer et Maladies Apparentées: Prise en charge des troubles du comportement perturbateurs 2009.
http://www.has-sante.fr/portail/jcms/c_819667/maladie-d-alzheimer-et-maladies-
apparentees-prise-en-charge-des-troubles-du-comportement-perturbateurs
[2] Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Örey, D., Richter, F., et al. (2013) Comparative Efficacy and Tolerability of 15 Antipsychotic Drugs in Schizophrenia: A Multiple-Treatments Meta-Analysis. The Lancet, 382, 951-962.
http://dx.doi.org/10.1016/S0140-6736(13)60733-3
[3] Schneider, L.S., Dagerman, K.S. and Insel, P. (2005) Risk of Death with Atypical Antipsychotic Drug Treatment for Dementia: Meta-Analysis of Randomized Placebo-Controlled Trials. JAMA, 294, 1934-1943.
http://dx.doi.org/10.1001/jama.294.15.1934
[4] Verdoux, H., Tournier, M. and Bégaud, B. (2010) Antipsychotic Prescribing Trends: A Review of Pharmaco-Epidemiological Studies. Acta Psychiatrica Scandinavica, 121, 4-10.
http://dx.doi.org/10.1111/j.1600-0447.2009.01425.x
[5] Maher, A., Maglione, M., Bagley, S., et al. (2011) Efficacy and Comparative Effectiveness of Atypical Antipsychotic Medications for Off-Label Uses in Adults: A Systematic Review and Meta-Analysis. JAMA, 306, 1359-1369.
http://dx.doi.org/10.1001/jama.2011.1360
[6] Alexander, G.C., Gallagher, S.A., Mascola, A., Moloney, R.M. and Stafford, R.S. (2011) Increasing Off-Label Use of Antipsychotic Medications in the United States, 1995-2008. Pharmacoepidemiology and Drug Safety, 20, 177-184.
http://dx.doi.org/10.1002/pds.2082
[7] Puyat, J.H., Law, M.R., Wong, S.T., Sutherland, J.M. and Morgan, S.G. (2012) The Essential and Potentially Inappropriate Use of Antipsychotics across Income Groups: An Analysis of Linked Administrative Data. Canadian Journal of Psychiatry Revue Canadienne de Psychiatrie, 57, 488.
[8] Tuppin, P., de Roquefeuil, L., Weill, A., Ricordeau, P. and Merlière, Y. (2010) French National Health Insurance Information System and the Permanent Beneficiaries Sample. Revue d’Epidémiologie et de Santé Publique, 58, 286-290.
http://dx.doi.org/10.1016/j.respe.2010.04.005
[9] European Medicines Agency and Heads of Medicines Agencies (2012) Guideline on Good Pharmacovigilance Practices (GVP)—Module VI: Management and Reporting of Adverse Reactions to Medicinal Products.
[10] Steiner, J.F. and Prochazka, A.V. (1997) The Assessment of Refill Compliance Using Pharmacy Records: Methods, Validity, and Applications. Journal of Clinical Epidemiology, 50, 105-116.
http://dx.doi.org/10.1016/S0895-4356(96)00268-5
[11] Lecadet, J., Bidal, P., Baris, B., Vallier, N., Fender, P., Allemand, H., et al. (2003) Médicaments psychotropes: Consommation et pratiques de prescription en France métropolitaine: I-Données nationales, 2000. Revue Médicale de l’Assurance Maladie, 34, 75-84.
[12] Diatta, T., Blazejewski, S., Portier, A., Lignot, S., Quesnot, A., Moore, N., et al. (2007) Patterns and Frequency of Atypical Antipsychotic Prescribing in Psychiatric Medical Centers: A Cross-Sectional National Survey. Fundamental & Clinical Pharmacology, 21, 371-378.
http://dx.doi.org/10.1111/j.1472-8206.2007.00492.x
[13] Kjosavik, S.R., Ruths, S. and Hunskaar, S. (2009) Psychotropic Drug Use in the Norwegian General Population in 2005: Data from the Norwegian Prescription Database. Pharmacoepidemiology and Drug Safety, 18, 572-578.
http://dx.doi.org/10.1002/pds.1756
[14] Gallini, A., Donohue, J.M. and Huskamp, H.A. (2013) Diffusion of Antipsychotics in the U.S. and French Markets, 1998-2008. Psychiatric Services, 64, 680-687.
http://dx.doi.org/10.1176/appi.ps.004662012
[15] Haute Autorité de Santé (2011) Avis Commission de la Transparence-XEROQUEL.
http://www.has-sante.fr/portail/jcms/c_1065592/fr/xeroquel?xtmc=&xtcr=4
[16] Laroche, M.-L., Charmes, J.-P. and Merle, L. (2007) Potentially Inappropriate Medications in the Elderly: A French Consensus Panel List. European Journal of Clinical Pharmacology, 63, 725-731.
http://dx.doi.org/10.1007/s00228-007-0324-2
[17] Rathbone, J. and Soares-Weiser, K. (2006) Anticholinergics for Neuroleptic-Induced Acute Akathisia. In: The Cochrane Collaboration and Rathbone, J., Eds., Cochrane Database of Systematic Reviews, John Wiley & Sons, Ltd., Chichester, Article No.: CD003727.
http://dx.doi.org/10.1002/14651858.cd003727.pub3
[18] Soares-Weiser, K., Mobsy, C. and Holliday, E. (1997) Anticholinergic Medication for Neuroleptic-Induced Tardive Dyskinesia. In: The Cochrane Collaboration and Mobsy, C., Eds., Cochrane Database of Systematic Reviews, John Wiley & Sons, Ltd., Chichester, Article No.: CD000204.
http://dx.doi.org/10.1002/14651858.cd000204
[19] Malfoy, K., Blanchon, M.-A., Lyonnet, A. and Gonthier, R. (2008) Impact sur les fonctions cognitives des anticholinergiques prescrits chez les patients agés de plus de 65 ans pour hyperactivité vésicale. NPG Neurologie-Psychiatrie-Gériatrie, 8, 6-15.
http://dx.doi.org/10.1016/j.npg.2008.09.003
[20] Leslie, D.L. and Rosenheck, R. (2012) Off-Label Use of Antipsychotic Medications in Medicaid. American Journal of Managed Care, 18, e109-e117.
[21] Chien, I.-C., Hsu, J.-H., Bih, S.-H., Lin, C.-H., Chou, Y.-J., Lee, C.-H., et al. (2008) Prevalence, Correlates, and Disease Patterns of Antipsychotic Use in Taiwan. Psychiatry and Clinical Neurosciences, 62, 677-684.
http://dx.doi.org/10.1111/j.1440-1819.2008.01869.x
[22] Wiechers, I.R., Leslie, D.L. and Rosenheck, R.A. (2013) Prescribing of Psychotropic Medications to Patients without a Psychiatric Diagnosis. Psychiatric Services, 64, 1243-1248.
http://dx.doi.org/10.1176/appi.ps.201200557
[23] Marston, L., Nazareth, I., Petersen, I., Walters, K. and Osborn, D.P.J. (2014) Prescribing of Antipsychotics in UK Primary Care: A Cohort Study. BMJ Open, 4, e006135.
http://dx.doi.org/10.1136/bmjopen-2014-006135
[24] Ballard, C. and Waite, J. (2006) The Effectiveness of Atypical Antipsychotics for the Treatment of Aggression and Psychosis in Alzheimer’s Disease. Cochrane Database of Systematic Reviews, 25, Article No.: CD003476.
[25] Schneider, L.S., Dagerman, K. and Insel, P.S. (2006) Efficacy and Adverse Effects of Atypical Antipsychotics for Dementia: Meta-Analysis of Randomized, Placebo-Controlled Trials. The American Journal of Geriatric Psychiatry, 14, 191-210.
http://dx.doi.org/10.1097/01.JGP.0000200589.01396.6d
[26] Arbus, C., Clement, J.-P., Bougerol, T., Fremont, P., Lancrenon, S. and Camus, V. (2012) Health Management of Older Persons with Chronically Medicated Psychotic Disorders: The Results of a Survey in France. International Psychogeriatrics, 24, 496-502.
http://dx.doi.org/10.1017/S1041610211001487
[27] Fourrier, A., Letenneur, L., Dartigues, J.F., Moore, N. and Bégaud, B. (2001) Benzodiazepine Use in an Elderly Community-Dwelling Population. Characteristics of Users and Factors Associated with Subsequent Use. European Journal of Clinical Pharmacology, 57, 419-425.
http://dx.doi.org/10.1007/s002280100326
[28] Percudani, M., Barbui, C., Fortino, I. and Petrovich, L. (2005) Antidepressant Drug Prescribing among Elderly Subjects: A Population-Based Study. International Journal of Geriatric Psychiatry, 20, 113-118.
http://dx.doi.org/10.1002/gps.1259

Journals Menu
Follow SCIRP
Contact us
customer@scirp.org
WhatsApp +86 18163351462(WhatsApp)
Click here to send a message to me 1655362766
Paper Publishing WeChat

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.